Breaking Finance News

Leerink Swann upgraded Mirati Therapeutics (NDAQ:MRTX) from Mkt Perform to Outperform in a statement released earlier today.

Leerink Swann has upgraded Mirati Therapeutics (NDAQ:MRTX) from Mkt Perform to Outperform in a statement released on 11/14/2017.

On Thursday October 12, 2017, H.C. Wainwright released a statement for Mirati Therapeutics (NDAQ:MRTX) bumped up the target price from $0.00 to $20.00 that suggested an upside of 0.42%.

Boasting a price of $13.07, Mirati Therapeutics (NDAQ:MRTX) traded 1.29% higher on the day. With the last stock price close up 170.15% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Mirati Therapeutics has recorded a 50-day average of $10.79 and a two hundred day average of $5.83. Volume of trade was down over the average, with 647,088 shares of MRTX changing hands under the typical 1,311,320

Performance Chart

Mirati Therapeutics (NDAQ:MRTX)

With a total market value of $0, Mirati Therapeutics has with a one year low of $2.70 and a one year high of $16.50 .

A total of 7 equity analysts have released a research note on MRTX. Four equity analysts rating the company a strong buy, two equity analysts rating the company a buy, one equity analyst rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $30.43.

More About Mirati Therapeutics (NDAQ:MRTX)

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *